{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:23:34Z","timestamp":1793820214265,"version":"4.6.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006182","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa e Inova\u00e7\u00e3o do Esp\u00edrito Santo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006182","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Harvard University, United States"},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01852-7","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:03:02Z","timestamp":1765540982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Inflammasome activation contributes to cisplatin resistance in ovarian cancer"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6777-0227","authenticated-orcid":false,"given":"Josiany Carlos","family":"de Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana Massariol","family":"Pimenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara da Silva","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Matheus Sim\u00f5es","family":"Padilha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenny Maria Silva","family":"Butzene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milleny Ganho","family":"Mar\u00e7al","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia Batista Azevedo","family":"Rangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"24","key":"1852_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246246","volume":"14","author":"KL Alatise","year":"2022","unstructured":"Alatise KL, Gardner S, Alexander-Bryant A. Mechanisms of drug resistance in ovarian cancer and associated gene targets. Cancers (Basel). 2022;14(24):6246. https:\/\/doi.org\/10.3390\/cancers14246246.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1852_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59071183","volume":"59","author":"C Arnaoutoglou","year":"2023","unstructured":"Arnaoutoglou C, Dampala K, Anthoulakis C, Papanikolaou EG, Tentas I, Dragoutsos G, et al. Epithelial ovarian cancer: a five year review. Medicina (Kaunas). 2023;59(7):1183. https:\/\/doi.org\/10.3390\/medicina59071183.","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"1852_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-023-05684-3","volume":"6","author":"K Barry","year":"2023","unstructured":"Barry K, Murphy C, Mansell A. NLRP1\u2014a cinderella story: a perspective of recent advances in NLRP1 and the questions they raise. Commun Biol. 2023;6(1):1274. https:\/\/doi.org\/10.1038\/s42003-023-05684-3.","journal-title":"Commun Biol"},{"issue":"6","key":"1852_CR4","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1007\/s10753-021-01493-0","volume":"44","author":"C Berkel","year":"2021","unstructured":"Berkel C, Cacan E. Differential expression and copy number variation of gasdermin (GSDM) family members, pore-forming proteins in pyroptosis, in normal and malignant serous ovarian tissue. Inflammation. 2021;44(6):2203\u201316. https:\/\/doi.org\/10.1007\/s10753-021-01493-0.","journal-title":"Inflammation"},{"issue":"7","key":"1852_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2016.58","volume":"16","author":"P Broz","year":"2016","unstructured":"Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16(7):407\u201320. https:\/\/doi.org\/10.1038\/nri.2016.58.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"1852_CR6","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1172\/JCI39065","volume":"119","author":"KA Charles","year":"2009","unstructured":"Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, et al. The tumor-promoting actions of TNF-\u03b1 involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest. 2009;119(10):3011\u201323. https:\/\/doi.org\/10.1172\/JCI39065.","journal-title":"J Clin Invest"},{"issue":"740","key":"1852_CR7","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"5","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;5(740):364\u201378. https:\/\/doi.org\/10.1016\/j.ejphar.2014.07.025.","journal-title":"Eur J Pharmacol"},{"key":"1852_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/or.2022.10568","volume":"16","author":"M Devanaboyina","year":"2022","unstructured":"Devanaboyina M, Kaur J, Whiteley E, Lin L, Einloth K, Morand S, et al. NF-\u03baB signaling in tumor pathways focusing on breast and ovarian cancer. Oncol Rev. 2022;16:10568. https:\/\/doi.org\/10.3389\/or.2022.10568.","journal-title":"Oncol Rev"},{"issue":"7","key":"1852_CR9","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41590-023-01526-w","volume":"24","author":"P Devant","year":"2023","unstructured":"Devant P, Kagan JC. Molecular mechanisms of gasdermin D pore-forming activity. Nat Immunol. 2023;24(7):1064\u201375. https:\/\/doi.org\/10.1038\/s41590-023-01526-w.","journal-title":"Nat Immunol"},{"key":"1852_CR10","doi-asserted-by":"publisher","first-page":"100924","DOI":"10.1016\/j.mam.2020.100924","volume":"76","author":"KP Down","year":"2020","unstructured":"Down KP, Nguyen H, Dorfleutner A, Stehlik C. An overview of the non-canonical inflammasome. Mol Aspects Med. 2020;76:100924. https:\/\/doi.org\/10.1016\/j.mam.2020.100924.","journal-title":"Mol Aspects Med"},{"key":"1852_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bpobgyn.2021.06.001","volume":"78","author":"A El Helali","year":"2022","unstructured":"El Helali A, Kwok GST, Tse KY. Adjuvant and post-surgical treatment in non-epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2022;78:74\u201385. https:\/\/doi.org\/10.1016\/j.bpobgyn.2021.06.001.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"1852_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.834072","volume":"12","author":"S Fakhri","year":"2022","unstructured":"Fakhri S, Moradi SZ, Yarmohammadi A, Narimani F, Wallace CE, Bishayee A. Modulation of TLR\/NF-\u03baB\/NLRP signaling by bioactive phytocompounds: a promising strategy to augment cancer chemotherapy and immunotherapy. Front Oncol. 2022;12:834072. https:\/\/doi.org\/10.3389\/fonc.2022.834072.","journal-title":"Front Oncol"},{"issue":"1","key":"1852_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-021-00724-8","volume":"28","author":"SS Faria","year":"2021","unstructured":"Faria SS, Costantini S, De Lima VCC, De Andrade VP, Rialland M, Cedric R, et al. Nlrp3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer. J Biomed Sci. 2021;28(1):26. https:\/\/doi.org\/10.1186\/s12929-021-00724-8.","journal-title":"J Biomed Sci"},{"key":"1852_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.102925","volume":"88","author":"S Ghosh","year":"2019","unstructured":"Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88:102925. https:\/\/doi.org\/10.1016\/j.bioorg.2019.102925.","journal-title":"Bioorg Chem"},{"issue":"4","key":"1852_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1108","volume":"11","author":"A Gonz\u00e1lez","year":"2023","unstructured":"Gonz\u00e1lez A, Garc\u00eda-G\u00f3mez-Heras S, Franco-Rodr\u00edguez R, L\u00f3pez-Miranda V, Herrad\u00f3n E. Cisplatin cycles treatment sustains cardiovascular and renal damage involving TLR4 and NLRP3 pathways. Pharmacol Res Perspect. 2023;11(4):e01108. https:\/\/doi.org\/10.1002\/prp2.1108.","journal-title":"Pharmacol Res Perspect"},{"key":"1852_CR16","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.2147\/CMAR.S292992","volume":"13","author":"T Guo","year":"2021","unstructured":"Guo T, Yang L, Sun M, Jiang J, Wang Q, Ma D, et al. Cellular mechanism of gene mutations and potential therapeutic targets in ovarian cancer. Cancer Manag Res. 2021;13:3081\u2013100. https:\/\/doi.org\/10.2147\/CMAR.S292992.","journal-title":"Cancer Manag Res"},{"key":"1852_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.humpath.2016.03.006","volume":"54","author":"M Gupta","year":"2016","unstructured":"Gupta M, Babic A, Beck AH, Terry K. TNF-\u03b1 expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis? Hum Pathol. 2016;54:82\u201391. https:\/\/doi.org\/10.1016\/j.humpath.2016.03.006.","journal-title":"Hum Pathol"},{"issue":"12","key":"1852_CR18","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","volume":"41","author":"Y He","year":"2016","unstructured":"He Y, Hara H, N\u00fa\u00f1ez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 2016;41(12):1012\u201321. https:\/\/doi.org\/10.1016\/j.tibs.2016.09.002.","journal-title":"Trends Biochem Sci"},{"issue":"2","key":"1852_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/eji.201746947","volume":"48","author":"R Heilig","year":"2018","unstructured":"Heilig R, Broz P. Function and mechanism of the pyrin inflammasome. Eur J Immunol. 2018;48(2):230\u20138. https:\/\/doi.org\/10.1002\/eji.201746947.","journal-title":"Eur J Immunol"},{"issue":"9","key":"1852_CR20","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/s41423-021-00740-6","volume":"18","author":"Y Huang","year":"2021","unstructured":"Huang Y, Xu W, Zhou R. Nlrp3 inflammasome activation and cell death. Cell Mol Immunol. 2021;18(9):2114\u201327. https:\/\/doi.org\/10.1038\/s41423-021-00740-6.","journal-title":"Cell Mol Immunol"},{"key":"1852_CR21","unstructured":"International Agency for Research on Cancer. Cancer Today (GLOBOCAN 2022). Lyon, France: IARC; 2022. Available from: https:\/\/gco.iarc.fr\/today\/en\/dataviz\/tables?mode=cancer&cancers=25&types=0&group_populations=1&multiple_populations=1&sexes=2. Cited 2025 May 19"},{"issue":"5","key":"1852_CR22","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1038\/s43018-023-00571-6","volume":"53","author":"H Jin","year":"2018","unstructured":"Jin H, Ko YS, Kim HJ. P2Y2R-mediated inflammasome activation is involved in tumor progression in breast cancer cells and in radiotherapy-resistant breast cancer. Int J Oncol. 2018;53(5):1953\u201366. https:\/\/doi.org\/10.1038\/s43018-023-00571-6.","journal-title":"Int J Oncol"},{"issue":"6","key":"1852_CR23","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s43018-023-00571-6","volume":"4","author":"H Kalkavan","year":"2023","unstructured":"Kalkavan H, R\u00fchl S, Shaw JJ, Green DR. Non-lethal outcomes of engaging regulated cell death pathways in cancer. Nat Cancer. 2023;4(6):795\u2013806. https:\/\/doi.org\/10.1038\/s43018-023-00571-6.","journal-title":"Nat Cancer"},{"key":"1852_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01132","volume":"8","author":"M Kantono","year":"2017","unstructured":"Kantono M, Guo B. Inflammasomes and cancer: the dynamic role of the inflammasome in tumor development. Front Immunol. 2017;8:1132. https:\/\/doi.org\/10.3389\/fimmu.2017.01132.","journal-title":"Front Immunol"},{"issue":"2","key":"1852_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2326-6066.CIR-16-0269","volume":"5","author":"R Karki","year":"2017","unstructured":"Karki R, Man SM, Kanneganti TD. Inflammasomes and cancer. Cancer Immunol Res. 2017;5(2):94\u20139. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0269.","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"1852_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10110433","volume":"10","author":"J Kim","year":"2018","unstructured":"Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, et al. Cell origins of high-grade serous ovarian cancer. Cancers (Basel). 2018;10(11):433. https:\/\/doi.org\/10.3390\/cancers10110433.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"1852_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2081-4","volume":"10","author":"M Kleih","year":"2019","unstructured":"Kleih M, B\u00f6pple K, Dong M, Gai\u00dfler A, Heine S, Olayioye MA. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death Dis. 2019;10(11):851. https:\/\/doi.org\/10.1038\/s41419-019-2081-4.","journal-title":"Cell Death Dis"},{"issue":"5","key":"1852_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3322\/caac.70008","volume":"75","author":"P Kordowitzki","year":"2025","unstructured":"Kordowitzki P, Lange B, Elias KM, Haigis MC, Mechsner S, Braicu IE, et al. Transforming treatment paradigms: focus on personalized medicine for high-grade serous ovarian cancer. CA Cancer J Clin. 2025;75(5):436\u201360. https:\/\/doi.org\/10.3322\/caac.70008.","journal-title":"CA Cancer J Clin"},{"key":"1852_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/934261","volume":"2014","author":"M Koshiyama","year":"2014","unstructured":"Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: type I and type II. BioMed Res Int. 2014;2014:934261. https:\/\/doi.org\/10.1155\/2014\/934261.","journal-title":"BioMed Res Int"},{"issue":"3","key":"1852_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3892\/ol.2025.14866","volume":"29","author":"M Kubo-Kaneda","year":"2025","unstructured":"Kubo-Kaneda M, Shimizu H, Takeda Y, Hiraki Y, Sakurai T, et al. Analysis of endometrial liquid-based cytology samples to detect somatic mutations and classify ovarian cancer. Oncol Lett. 2025;29(3):119. https:\/\/doi.org\/10.3892\/ol.2025.14866.","journal-title":"Oncol Lett"},{"issue":"1","key":"1852_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.seminoncol.2025.152337","volume":"52","author":"BB Kuriakose","year":"2025","unstructured":"Kuriakose BB, Zwamel AH, Mutar AA, Uthirapathy S, Bishoyi AK, Naidu KS, et al. The critical role of NLRP3 in drug resistance of cancers: focus on the molecular mechanisms and possible therapeutics. Semin Oncol. 2025;52(1):27\u201340. https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152337.","journal-title":"Semin Oncol"},{"issue":"1","key":"1852_CR32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/AOG.0000000000004173","volume":"1","author":"KC Kurnit","year":"2021","unstructured":"Kurnit KC, Fleming GF, Lengyel E. Updates and new options in advanced epithelial ovarian cancer treatment. Obstet Gynecol. 2021;1(1):108\u201321. https:\/\/doi.org\/10.1097\/AOG.0000000000004173.","journal-title":"Obstet Gynecol"},{"issue":"9","key":"1852_CR33","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1007\/s00261-025-04842-x","volume":"50","author":"J Li","year":"2025","unstructured":"Li J, Wang Y, Zhang H, Liu X, Chen Q, et al. A clinicoradiological model based on clinical and CT features for preoperative prediction of histological classification in patients with epithelial ovarian cancers: a two-center study. Abdom Radiol (NY). 2025;50(9):4331\u201341. https:\/\/doi.org\/10.1007\/s00261-025-04842-x.","journal-title":"Abdom Radiol (NY)"},{"issue":"10","key":"1852_CR34","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/abbs\/gmaa097","volume":"52","author":"Q Li","year":"2020","unstructured":"Li Q, Wang M, Zhang Y, Wang L, Yu W, Bao X, et al. BIX-01294-enhanced chemosensitivity in nasopharyngeal carcinoma depends on autophagy-induced pyroptosis. Acta Biochim Biophys Sin. 2020;52(10):1131\u20139. https:\/\/doi.org\/10.1093\/abbs\/gmaa097.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"1","key":"1852_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.07.001","volume":"383","author":"S Li","year":"2019","unstructured":"Li S, Lin Q, Shao X, Mou S, Gu L, Wang L, et al. Nlrp3 inflammasome inhibition attenuates cispltin-induced renal fibrosis by decreasing oxidative stress and inflammation. Exp Cell Res. 2019;383(1):111488. https:\/\/doi.org\/10.1016\/j.yexcr.2019.07.001.","journal-title":"Exp Cell Res"},{"key":"1852_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/7700673","volume":"2023","author":"W Li","year":"2023","unstructured":"Li W, Zhao X, Zhang R, Xie J, Zhang G. Silencing of NLRP3 sensitizes chemoresistant ovarian cancer cells to cisplatin. Mediators Inflamm. 2023;2023:7700673. https:\/\/doi.org\/10.1155\/2023\/7700673.","journal-title":"Mediators Inflamm"},{"key":"1852_CR37","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2147\/JIR.S503479","volume":"18","author":"C Liu","year":"2025","unstructured":"Liu C, Yin Q, Wu Z, Li W, Huang J, Chen B, et al. Inflammation and immune escape in ovarian cancer: pathways and therapeutic opportunities. J Inflamm Res. 2025;18:895\u2013909. https:\/\/doi.org\/10.2147\/JIR.S503479.","journal-title":"J Inflamm Res"},{"key":"1852_CR38","doi-asserted-by":"publisher","first-page":"5440","DOI":"10.1016\/j.csbj.2022.09.037","volume":"20","author":"J Liu","year":"2022","unstructured":"Liu J, Chen C, Geng R, et al. Pyroptosis-related gene expression patterns and corresponding tumor microenvironment infiltration characterization in ovarian cancer. Comput Struct Biotechnol J. 2022;20:5440\u201352. https:\/\/doi.org\/10.1016\/j.csbj.2022.09.037.","journal-title":"Comput Struct Biotechnol J"},{"key":"1852_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.828303","volume":"12","author":"T Liu","year":"2022","unstructured":"Liu T, Hou M, Li M, Qiu C, Cheng L, Zhu T, et al. Pyroptosis: a developing foreland of ovarian cancer treatment. Front Oncol. 2022;12:828303. https:\/\/doi.org\/10.3389\/fonc.2022.828303.","journal-title":"Front Oncol"},{"key":"1852_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01101-6","volume":"8","author":"L Lu","year":"2022","unstructured":"Lu L, Zhang Y, Tan X, et al. Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer. Cell Death Discov. 2022;8:338. https:\/\/doi.org\/10.1038\/s41420-022-01101-6.","journal-title":"Cell Death Discov"},{"issue":"1","key":"1852_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227081","volume":"15","author":"J Luborsky","year":"2020","unstructured":"Luborsky J, Barua A, Edassery S, Bahr JM. Inflammasome expression is higher in ovarian tumors than in normal ovary. PLoS ONE. 2020;15(1):e0227081. https:\/\/doi.org\/10.1371\/journal.pone.0227081.","journal-title":"PLoS ONE"},{"issue":"1","key":"1852_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nri.2015.7","volume":"16","author":"SM Man","year":"2016","unstructured":"Man SM, Kanneganti TD. Converging roles of caspases in inflammasome activation, cell death and innate immunity. Nat Rev Immunol. 2016;16(1):7\u201321. https:\/\/doi.org\/10.1038\/nri.2015.7.","journal-title":"Nat Rev Immunol"},{"key":"1852_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.61","volume":"2","author":"UA Matulonis","year":"2016","unstructured":"Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061. https:\/\/doi.org\/10.1038\/nrdp.2016.61.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"1852_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102297","volume":"13","author":"S Missiroli","year":"2021","unstructured":"Missiroli S, Perrone M, Boncompagni C, Borghi C, Campagnaro A, Marchetti F, et al. Targeting the NLRP3 inflammasome as a new therapeutic option for overcoming cancer. Cancers (Basel). 2021;13(11):2297. https:\/\/doi.org\/10.3390\/cancers13102297.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1852_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0900-3","volume":"17","author":"M Moossavi","year":"2018","unstructured":"Moossavi M, Parsamanesh N, Bahrami A, Atkin SL, Sahebkar A. Role of the NLRP3 inflammasome in cancer. Mol Cancer. 2018;17(1):158. https:\/\/doi.org\/10.1186\/s12943-018-0900-3.","journal-title":"Mol Cancer"},{"issue":"12","key":"1852_CR46","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.11817\/j.issn.1672-7347.2023.230231","volume":"48","author":"T Niu","year":"2023","unstructured":"Niu T, Zhou F. Inflammation and tumor microenvironment. J Cent South Univ Med Sci. 2023;48(12):1899\u2013913. https:\/\/doi.org\/10.11817\/j.issn.1672-7347.2023.230231.","journal-title":"J Cent South Univ Med Sci"},{"issue":"6","key":"1852_CR47","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.hoc.2018.07.010","volume":"32","author":"B Orr","year":"2018","unstructured":"Orr B, Edwards RP. Diagnosis and treatment of ovarian cancer. Hematol Oncol Clin North Am. 2018;32(6):943\u201364. https:\/\/doi.org\/10.1016\/j.hoc.2018.07.010.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"13","key":"1852_CR48","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2147\/ITT.S495564","volume":"14","author":"W Pan","year":"2024","unstructured":"Pan W, Jia Z, Du J, Chang K, Liu Y, Liu W, et al. NLRP3 inflammasome upregulates PD-L1 in ovarian cancer and contributes to an immunosuppressive microenvironment. ImmunoTargets Ther. 2024;14(13):775\u201388. https:\/\/doi.org\/10.2147\/ITT.S495564.","journal-title":"ImmunoTargets Ther"},{"issue":"1","key":"1852_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13406","volume":"329","author":"A Pandey","year":"2025","unstructured":"Pandey A, Li Z, Gautam M, Ghosh A, Man SM. Molecular mechanisms of emerging inflammasome complexes and their activation and signaling in inflammation and pyroptosis. Immunol Rev. 2025;329(1):e13406. https:\/\/doi.org\/10.1111\/imr.13406.","journal-title":"Immunol Rev"},{"key":"1852_CR50","unstructured":"Petrucelli N, Daly MB, Pal T.\u00a0BRCA1-\u00a0and\u00a0BRCA2-Associated Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [updated 2025 Mar 20]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews\u00ae\u00a0. Seattle (WA): University of Washington, Seattle; 1993\u20132025."},{"issue":"7","key":"1852_CR51","doi-asserted-by":"publisher","first-page":"53","DOI":"10.20517\/cdr.2024.111","volume":"17","author":"A Ponton-Almodovar","year":"2024","unstructured":"Ponton-Almodovar A, Sanderson S, Rattan R, Bernard JJ, Horibata S. Ovarian tumor microenvironment contributes to tumor progression and chemoresistance. Cancer Drug Resist. 2024;17(7):53. https:\/\/doi.org\/10.20517\/cdr.2024.111.","journal-title":"Cancer Drug Resist"},{"issue":"9","key":"1852_CR52","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.7150\/thno.71086","volume":"12","author":"Z Rao","year":"2022","unstructured":"Rao Z, Zhu Y, Yang P, et al. Pyroptosis in inflammatory diseases and cancer. Theranostics. 2022;12(9):4310\u20139. https:\/\/doi.org\/10.7150\/thno.71086.","journal-title":"Theranostics"},{"key":"1852_CR53","unstructured":"Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, Minor L. Cell Viability Assays. In: Markossian S, Grossman A, Baskir H, Arkin M, Auld D, Austin C, Baell J, Brimacombe K, Chung TDY, Coussens NP, Dahlin JL, Devanarayan V, Foley TL, Glicksman M, Gorshkov K, Grotegut S, Hall MD, Hoare S, Inglese J, Iversen PW, Lal-Nag M, Li Z, Manro JR, McGee J, Norvil A, Pearson M, Riss T, Saradjian P, Sittampalam GS, Tarselli MA, Trask OJ Jr, Weidner JR, Wildey MJ, Wilson K, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda : Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004. PMID: 23805433.\u00a02013 May 1 [updated 2016 Jul 1]."},{"issue":"12","key":"1852_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17122113","volume":"17","author":"V Rojas","year":"2016","unstructured":"Rojas V, Hirshfield KM, Ganesan S, Rodriguez-Rodriguez L. Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment. Int J Mol Sci. 2016;17(12):2113. https:\/\/doi.org\/10.3390\/ijms17122113.","journal-title":"Int J Mol Sci"},{"key":"1852_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100629","volume":"33","author":"S Sambasivan","year":"2022","unstructured":"Sambasivan S. Epithelial ovarian cancer: review article. Cancer Treat Res Commun. 2022;33:100629. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100629.","journal-title":"Cancer Treat Res Commun"},{"issue":"8","key":"1852_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10080251","volume":"10","author":"S Savant","year":"2018","unstructured":"Savant S, Sriramkumar S, O\u2019Hagan H. The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer. Cancers (Basel). 2018;10(8):251. https:\/\/doi.org\/10.3390\/cancers10080251.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1852_CR57","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676\u201382. https:\/\/doi.org\/10.1038\/nmeth.2019.","journal-title":"Nat Methods"},{"key":"1852_CR58","doi-asserted-by":"publisher","unstructured":"Shaheen M, Radolec M, Jones P, Panesso S, Krishnan S, Munguia F, Yilmaz S, Edwards RP, Olawaiye AB, Mahdi H. NLRP3 inflammasome targeting to overcome platinum and PARPi resistance by modulating cancer related inflammation in ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; 2025 Apr 25\u201330; Chicago, IL. Philadelphia (PA): AACR; Cancer Res. 2025;85(8 Suppl 1):Abstract nr 2172. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-2172.","DOI":"10.1158\/1538-7445.AM2025-2172"},{"issue":"5","key":"1852_CR59","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41590-021-00886-5","volume":"22","author":"BR Sharma","year":"2021","unstructured":"Sharma BR, Kanneganti TD. Nlrp3 inflammasome in cancer and metabolic diseases. Nat Immunol. 2021;22(5):550\u20139. https:\/\/doi.org\/10.1038\/s41590-021-00886-5.","journal-title":"Nat Immunol"},{"issue":"4","key":"1852_CR60","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/s1535-6108(03)00058-8","volume":"3","author":"CA Sherman-Baust","year":"2003","unstructured":"Sherman-Baust CA, Weeraratna AT, Rangel LB, Pizer ES, Cho KR, Schwartz DR, et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to Cisplatin resistance in ovarian cancer cells. Cancer Cell. 2003;3(4):377\u201386. https:\/\/doi.org\/10.1016\/s1535-6108(03)00058-8.","journal-title":"Cancer Cell"},{"issue":"1","key":"1852_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-025-13652-9","volume":"25","author":"W Shi","year":"2025","unstructured":"Shi W, Li J, Wang Y, Zhang L, Chen M, Liu X, et al. Protocol of the SOCFC project: a longitudinal cohort study of ovarian cancer patients, high-risk populations, and healthy controls to identify factors and biomarkers associated with disease diagnosis and prognosis. BMC Cancer. 2025;25(1):1\u20138. https:\/\/doi.org\/10.1186\/s12885-025-13652-9.","journal-title":"BMC Cancer"},{"issue":"1","key":"1852_CR62","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ajpath.2020.09.006","volume":"191","author":"IM Shih","year":"2021","unstructured":"Shih IM, Wang Y, Wang TL. The origin of ovarian cancer species and precancerous landscape. Am J Pathol. 2021;191(1):26\u201339. https:\/\/doi.org\/10.1016\/j.ajpath.2020.09.006.","journal-title":"Am J Pathol"},{"key":"1852_CR63","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"key":"1852_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114205","volume":"232","author":"M Song","year":"2022","unstructured":"Song M, Cui M, Liu K. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur J Med Chem. 2022;232:114205. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114205.","journal-title":"Eur J Med Chem"},{"issue":"17","key":"1852_CR65","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1200\/JCO.21.02016","volume":"40","author":"MP Steenbeek","year":"2022","unstructured":"Steenbeek MP, van Bommel MHD, Bulten J, Hulsmann JA, Bogaerts J, Garcia C, et al. Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy: a systematic review and individual patient data meta-analysis. J Clin Oncol. 2022;40(17):1879\u201391. https:\/\/doi.org\/10.1200\/JCO.21.02016.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1852_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188639","volume":"1876","author":"I Szulc-Kielbik","year":"2021","unstructured":"Szulc-Kielbik I, Kielbik M, Nowak M, Klink M. The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients. Biochimica et Biophysica Acta (BBA). 2021;1876(2):188639. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188639.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"1","key":"1852_CR67","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/cam4.4927","volume":"12","author":"N Takahashi","year":"2023","unstructured":"Takahashi N, Hatakeyama K, Nagashima T, Ohshima K, Urakami K, Yamaguchi K, et al. Characterization of rare histological subtypes of ovarian cancer based on molecular profiling. Cancer Med. 2023;12(1):387\u201395. https:\/\/doi.org\/10.1002\/cam4.4927.","journal-title":"Cancer Med"},{"issue":"1","key":"1852_CR68","doi-asserted-by":"publisher","first-page":"9728","DOI":"10.1038\/s41598-017-10432-9","volume":"7","author":"JK Teer","year":"2017","unstructured":"Teer JK, Bonny AR, Hurley RM, Hoadley KA, Wolff DJ, Hayes DN, et al. Mutational heterogeneity in non-serous ovarian cancers. Sci Rep. 2017;7(1):9728. https:\/\/doi.org\/10.1038\/s41598-017-10432-9.","journal-title":"Sci Rep"},{"issue":"6","key":"1852_CR69","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2174\/1871520620666200908104835","volume":"21","author":"S Tendulkar","year":"2021","unstructured":"Tendulkar S, Dodamani S. Chemoresistance in ovarian cancer: prospects for new drugs. Anticancer Agents Med Chem. 2021;21(6):668\u201378. https:\/\/doi.org\/10.2174\/1871520620666200908104835.","journal-title":"Anticancer Agents Med Chem"},{"key":"1852_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108545","volume":"251","author":"IW Tengesdal","year":"2023","unstructured":"Tengesdal IW, Dinarello CA, Marchetti C. NLRP3 and cancer: pathogenesis and therapeutic opportunities. Pharmacol Ther. 2023;251:108545. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108545.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"1852_CR71","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2016.27.e25","volume":"27","author":"KY Terada","year":"2016","unstructured":"Terada KY, Ahn HJ, Kessel B. Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial. J Gynecol Oncol. 2016;27(3):e25. https:\/\/doi.org\/10.3802\/jgo.2016.27.e25.","journal-title":"J Gynecol Oncol"},{"issue":"7353","key":"1852_CR72","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","unstructured":"The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609\u201315. https:\/\/doi.org\/10.1038\/nature10166.","journal-title":"Nature"},{"key":"1852_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00123","volume":"11","author":"W Tian","year":"2020","unstructured":"Tian W, Wang Z, Tang NN, Li JT, Liu Y, Chu WF, et al. Ascorbic acid sensitizes colorectal carcinoma to the cytotoxicity of arsenic trioxide via promoting reactive oxygen species-dependent apoptosis and pyroptosis. Front Pharmacol. 2020;11:123. https:\/\/doi.org\/10.3389\/fphar.2020.00123.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1852_CR74","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1073\/pnas.0437939100","volume":"100","author":"E Voronov","year":"2003","unstructured":"Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003;100(5):2645\u201350. https:\/\/doi.org\/10.1073\/pnas.0437939100.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1852_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.189058","volume":"1879","author":"A Wang","year":"2024","unstructured":"Wang A, Wang Y, Du C, et al. Pyroptosis and the tumor immune microenvironment: a new battlefield in ovarian cancer treatment. Biochimica et Biophysica Acta (BBA). 2024;1879(2):189058. https:\/\/doi.org\/10.1016\/j.bbcan.2023.189058.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"5","key":"1852_CR76","doi-asserted-by":"publisher","first-page":"761","DOI":"10.7150\/jca.17648","volume":"8","author":"M Wang","year":"2017","unstructured":"Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8(5):761\u201373. https:\/\/doi.org\/10.7150\/jca.17648.","journal-title":"J Cancer"},{"issue":"1","key":"1852_CR77","doi-asserted-by":"publisher","DOI":"10.1172\/JCI174013","volume":"134","author":"Y Wang","year":"2024","unstructured":"Wang Y, Duval AJ, Adli M, Matei D. Biology-driven therapy advances in high-grade serous ovarian cancer. J Clin Invest. 2024;134(1):e174013. https:\/\/doi.org\/10.1172\/JCI174013.","journal-title":"J Clin Invest"},{"key":"1852_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145404","volume":"10","author":"C Westbom","year":"2015","unstructured":"Westbom C, Thompson JK, Leggett A, MacPherson M, Beuschel S, Pass H, et al. Inflammasome modulation by chemotherapeutics in malignant mesothelioma. PLoS ONE. 2015;10:e0145404. https:\/\/doi.org\/10.1371\/journal.pone.0145404.","journal-title":"PLoS ONE"},{"key":"1852_CR79","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ebiom.2019.02.012","volume":"41","author":"M Wu","year":"2019","unstructured":"Wu M, Wang Y, Yang D, Gong Y, Rao F, Liu R, et al. A PLK1 kinase inhibitor enhances the chemosensitivity of Cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma. EBioMedicine. 2019;41:244\u201355. https:\/\/doi.org\/10.1016\/j.ebiom.2019.02.012.","journal-title":"EBioMedicine"},{"issue":"10","key":"1852_CR80","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.7150\/ijbs.60292","volume":"17","author":"H Yan","year":"2021","unstructured":"Yan H, Luo B, Wu X, Guan F, Yu X, Zhao L, et al. Cisplatin induces pyroptosis via activation of MEG3\/NLRP3\/caspase-1\/GSDMD pathway in triple-negative breast cancer. Int J Biol Sci. 2021;17(10):2606\u201321. https:\/\/doi.org\/10.7150\/ijbs.60292.","journal-title":"Int J Biol Sci"},{"issue":"11","key":"1852_CR81","doi-asserted-by":"publisher","DOI":"10.2196\/25976","volume":"7","author":"SP Yang","year":"2021","unstructured":"Yang SP, Su HL, Chen XB, Hua L, Chen JX, Hu M, et al. Long-term survival among histological subtypes in advanced epithelial Ovarian cancer: population-based study using the surveillance, epidemiology, and end results database. JMIR Public Health Surveill. 2021;7(11):e25976. https:\/\/doi.org\/10.2196\/25976.","journal-title":"JMIR Public Health Surveill"},{"key":"1852_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.823439","volume":"13","author":"W Yu","year":"2022","unstructured":"Yu W, Zong S, Zhou P, Wei J, Wang E, Ming R, et al. Cochlear marginal cell pyroptosis is induced by cisplatin via NLRP3 inflammasome activation. Front Immunol. 2022;13:823439. https:\/\/doi.org\/10.3389\/fimmu.2022.823439.","journal-title":"Front Immunol"},{"issue":"10","key":"1852_CR83","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30561","volume":"14","author":"UM Zamwar","year":"2022","unstructured":"Zamwar UM, Anjankar AP. Aetiology, epidemiology, histopathology, classification, detailed evaluation, and treatment of ovarian cancer. Cureus. 2022;14(10):e30561. https:\/\/doi.org\/10.7759\/cureus.30561.","journal-title":"Cureus"},{"issue":"6","key":"1852_CR84","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1038\/onc.2017.26","volume":"36","author":"Z Zhai","year":"2017","unstructured":"Zhai Z, Liu W, Kaur M, Luo Y, Domenico J, Samson JM, et al. NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene. 2017;36(6):3820\u201330. https:\/\/doi.org\/10.1038\/onc.2017.26.","journal-title":"Oncogene"},{"issue":"5\u20136","key":"1852_CR85","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s10495-019-01515-1","volume":"24","author":"CC Zhang","year":"2019","unstructured":"Zhang CC, Li CG, Wang YF, Xu LH, He XH, Zeng QZ, et al. Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3\/GSDME activation. Apoptosis. 2019;24(5\u20136):312\u201325. https:\/\/doi.org\/10.1007\/s10495-019-01515-1.","journal-title":"Apoptosis"},{"issue":"9","key":"1852_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108475","volume":"50","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, et al. The impact of laterality on the incidence and prognosis of epithelial ovarian cancer. Eur J Surg Oncol. 2024;50(9):108475. https:\/\/doi.org\/10.1016\/j.ejso.2024.108475.","journal-title":"Eur J Surg Oncol"},{"key":"1852_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00577","volume":"8","author":"J Zhou","year":"2018","unstructured":"Zhou J, Wu SG, Wang J, Sun JY, He ZY, Jin X, et al. The effect of histological subtypes on outcomes of stage IV epithelial ovarian cancer. Front Oncol. 2018;8:577. https:\/\/doi.org\/10.3389\/fonc.2018.00577.","journal-title":"Front Oncol"},{"issue":"8","key":"1852_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087585","volume":"24","author":"A Zo\u0144","year":"2023","unstructured":"Zo\u0144 A, Bednarek I. Cisplatin in ovarian cancer treatment\u2014known limitations in therapy force new solutions. Int J Mol Sci. 2023;24(8):7585. https:\/\/doi.org\/10.3390\/ijms24087585.","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01852-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01852-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01852-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:03:06Z","timestamp":1765540986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-025-01852-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1852"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01852-7","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"294"}}